Baird Lifts Price Target On Optimer (OPTR) On Premium Price and Confidence About Label
Tweet Send to a Friend
Baird raised their price target on Optimer Pharmaceuticals (NASDAQ: OPTR) from $16 to $18 following the Dificid (fidaxomicin) approval conference ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
